Published on
September 21, 2023
- 12:00 GMT
Innovative Decentralized ME&MGopen Clinical Study In Myasthenia Gravis Is Off To A Good Start
The ME&MGopen study has already recruited 165 patients in the USA and 11 in Canada. This innovative program is supported by Alexion, AstraZeneca Rare Disease. PARIS, FRANCE, September 21, 2023 /EINPresswire.com/ -- Generalized Myasthenia Gravis (gMG …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
